Debiopharm signs licensing pact with Shasun Pharma

The pact is for the manufacturing and commercialisation of Huperzine-A.

 

New Delhi, April 10, 2013: Shasun Pharmaceuticals has entered with a licensing apct with Switzerland-based Debiopharm for the manufacturing and commercialisation of Huperzine-A (a drug used in the treatment of Alzheimer’s disease).

 

As per the agreement, Shasun Pharmaceuticals would be able to use the Debiopharm technology for manufacturing synthetic Huperzine-A and commercialise it.

 

Comment!
 
 






* Indicates mandatory field.
Please wait while comments are being sent...